Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Bardet-Biedl syndrome is most often covered alongside Duquesne Family Office, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Bardet-Biedl syndrome, all published on August 24, 2026.
Last mentioned: 1h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Bardet-Biedl syndrome is most often covered alongside Duquesne Family Office, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Bardet-Biedl syndrome, all published on August 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bardet-Biedl syndrome. Shared-story counts are live from our verified record — not editorial picks.
Rhythm Pharmaceuticals' Imcivree targets rare genetic obesity forms that GLP-1 leaders Eli Lilly and Novo Nordisk don't treat. With a U.S.-Europe market of up to 7,500 patients and a new Druckenmiller-backed position, healthcare stakeholders are watching a distinct orphan drug niche.
Bardet-Biedl syndrome is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
